Nanjing Entai Medical Science & Technology

The company has completed a Phase III randomized, double-blind, placebo-controlled multicenter clinical trial evaluating the efficacy and safety of amisulpride injection in preventing postoperative nausea and vomiting. It has also conducted a pharmacokinetic/bioequivalence study comparing its aprepitant injection to CINVANTI® in healthy subjects[1].

No published commercial results or approvals are noted as of March 2025.

Pipeline breadth appears limited to two main programs based on available data.

No evidence of broader late-stage pipeline or marketed products found in public sources as of March 2025.

The company operates as a private subsidiary founded in Jiangsu Province, China since at least 2013[1].

Website listed as www.entaipharm.com[1].

No evidence found for stock exchange listing or major partnerships.